Abstract: The Chemical-agent Access and Neutralization System (CANS) of the present invention is a small, portable, single-use, disposable chemical treatment apparatus that is used to access and treat Chemical Agent Identification Set (CAIS) ampoules, bottles and/or containers that contain vesicant agents, or chemical warfare agents such as mustard or Lewisite. The apparatus and method of use of the present invention provides a resultant treatment residue that remains totally contained in the CANS treatment container and is safe for disposal. The CANS treatment container can be over packed into a Department of Transportation (DOT) certified shipping container, and shipped to permitted hazardous waste management facilities for ultimate disposal.

Abstract: An object of the present invention is to provide a new method for treating an exhaust gas, which can effectively treat an exhaust gas containing a nitrogen oxide and metal mercury over a long term, and also can be applied to treatment of a large volume of an exhaust gas. As a means of achieving this object, a method according to the present invention for treating an exhaust gas comprises performing a reaction of changing metal mercury into mercury halide in the presence of a halogen compound and treatment of a nitrogen oxide, using a Ti—V-containing catalyst, upon treatment of an exhaust gas containing a nitrogen oxide and metal mercury.

Abstract: A method of selectively catalysing the reduction of NOx in an exhaust gas flowing in an exhaust system of an internal combustion engine comprising a filter (40) for particulate matter comprising a catalyst capable of selectively catalysing the reduction of NOx with a reducing agent, which method comprising introducing a reducing agent, or a precursor thereof, into the exhaust gas and contacting the resulting gas with the filter (40).

Abstract: Hydrogen sulfide and mercaptans may be removed from a fluid or gaseous stream by reacting the hydrogen sulfide and mercaptans in the stream with a scavenger selected from a: (i.) 1,3,5-trisalkanylamino hexahydro-1,3,5-triazine derivative; (ii.) morpholine or piperazine derivative; (iii.) amine oxide; (iv.) alkanolamine; or (v.) aliphatic or aromatic polyamine.

Abstract: Polycrystalline cerium oxide powder in the form of aggregates of primary particles with a specific surface of between 70 and 150 m2/g, an average primary particle diameter of between 5 and 20 nm and an average, projected aggregate diameter of between 20 and 100 nm. It is produced in that an aerosol is reacted in a flame obtained from a hydrogen-containing combustible gas and primary air and the solid obtained is then separated from the gaseous substances.

Abstract: Materials that are useful for absorption enhanced reforming (AER) of a fuel, including absorbent materials and catalyst materials and methods for using the materials. The materials can be fabricated by spray processing. The use of the materials in AER can produce a H2 product gas having a high H2 content and a low level of carbon oxides.

Abstract: A colloidal suspension of LEV structure type crystalline molecular sieve, making the suspension by washing smaller crystallites from a previously found solid LEV product, and using the suspension as seeds in further crystalline molecular sieve syntheses.

Abstract: A compound represented by the following general formula (I) or a salt thereof: wherein Ar1 and Ar2 independently represent a substituted or unsubstituted aryl group having at least one iodine atom as a substituent; L1 and L2 independently represent a divalent bridging group of which main chain consists of 7 or more atoms at least one of which is a heteroatom; and X represents —CH(OH)— or —CO—, which is suitable for an iodine-containing contrast medium containing liposomes.

Abstract: The present invention relates to a preparation method for technetium-antimony trisulfide nanocolloid, more precisely, a preparation method for technetium-antimony trisulfide nanocolloid which is characterized by the processes of mixing and stirring or irradiating of pertechnetate and antimony sulfide nanocolloid in the presence of borohydride exchange resin to obtain the technetium-antimony trisulfide nanocolloid radioactive complex.

Abstract: A process for the production of an 18F-labelled tracer which comprises treatment of a solid support-bound precursor of formula (I): SOLID SUPPORT-LINKER-SO2—O-TRACER (I) with 18F— to produce the labelled tracer of formula (II)

Abstract: An Numb protein expression inhibitor comprising, as active ingredient, Musashi protein, a polypeptide having an amino acid sequence obtained by replacement, deletion, addition or insertion of at least one amino acid in an amino acid sequence of Musashi protein, or a gene encoding said polypeptide. By the present invention, a new function of Musashi protein has been elucidated. Described specifically, Musashi protein inhibits expression of Numb protein having a neuronal differentiation regulating function and potentiates the activity of the Notch signaling system, so that Musashi protein can be used as a therapeutic for various diseases of the central nervous system.

Abstract: The present invention provides methods and systems for performing in-vivo flow cytometry to obtain desired information regarding one or more cell types of interest flowing through a subject's circulatory system. In one embodiment of the invention, a portion of the subject's circulating blood is illuminated with radiation having multiple wavelength components, and the backscattered radiation generated in response to the excitation radiation is detected at a plurality of scattering angles and analyzed to derive the desired information.

Abstract: The present invention relates to a composition having UV protection properties, charaterized in that the formulation comprises at least one encapsulated organic sunscreen and does not penetrate the skin essentially.

Abstract: The present invention provides for wood based panels (e.g., OSB or plywood) that are termite resistant, fungal resistant, or a combination thereof; and methods of manufacturing the same.

Abstract: A composition comprising an antiperspirant or deodorant active and which is substantially free of alcohol and has a viscosity of less than 100 centipoise and a contact angle less than 90°. A product comprising the composition marketed in a porous dome applicator.

Abstract: The present invention relates to a method of increasing the sensitivity of neoplastic cells to chemotherapeutic agents by using a virus, a method of treating proliferative disorders with a virus and chemotherapeutic agents, and a method for preventing a neoplasm from developing drug resistance to chemotherapeutic agents. The virus is preferably a reovirus.

Abstract: Heparinase enzymes can be used as a medical treatment to reduce localized inflammatory responses. Treatment of activated endothelium with heparinase inhibits leukocyte rolling, adhesion and extravasation. Most of the heparin and heparan sulfate on endothelial cell surfaces and in basement membranes is degraded by exposure to heparinase. In addition, immobilized chemokines, which are attached to heparin/heparan sulfate on activated endothelium are solubilized by heparinase digestion. Heparinase can be infused into the vascular system to inhibit accumulation of leukocytes in inflamed tissue and decrease damage resulting from localized inflammations. Targeting of heparinase to activated endothelium can be accomplished through localized administration and/or use of genetically engineered heparinase containing endothelium ligand-binding domains.

Abstract: Improvements in methods of treating cancer with weakly basic anti-cancer compounds are provided. In one aspect, the invention provides an improvement in a method of treating cancer cells whose extracellular environment contains 1–8 mM urea, by exposing the cells to a weakly basic anti-cancer compound which is effective in inhibiting the growth of the cells. The improvement includes (a) exposing the cells to a urease enzyme composition and, (b) by step (a), reducing the amount of anti-cancer compound required to produce a given extent of inhibition in the growth of the cells when the cells are exposed to the anti-cancer agent. Methods of potentiating the specific therapeutic activity of a weakly basic anti-cancer compound in the treatment of a given mammalian cancer which is responsive to the compound are provided as are pharmaceutical compositions for use in intravenous administration to a subject are also provided.

Abstract: The present invention is directed to novel polypeptides designated herein as EG-VEGF and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Also provided herein are methods of screening for modulators of EG-VEGF. Furthermore, methods and related methods of treatment are described herein which pertain to regulating cellular proliferation and chemotaxis.

Abstract: The present invention provides a purified preparation containing, for example, at least one polypeptide selected from the group consisting of proteins encoded by one or more open reading frames (ORF's) of an Iowa strain of porcine reproductive and respiratory syndrome virus (PRRSV), antigenic regions of such proteins which are at least 5 amino acids in length and which effectively protect a porcine host against a subsequent challenge with a PRRSV isolate, and combinations thereof in which amino acids non-essential for antigenicity may be conservatively substituted. The present invention also concerns a vaccine comprising an effective amount of such a protein; antibodies which specifically bind to such a protein; methods of producing the same; and methods of protecting a pig against a PRRSV, treating a pig infected by a PRRSV, and detecting PRRSV in a pig.

Abstract: A method of treating pulmonary hypertension in a subject in need of such treatment comprises inhibiting EMAP II activity in the subject by an amount effective to treat the pulmonary hypertension in the subject (e.g., in the lungs and more particularly in the pulmonary vasculature). Pharmaceutical formulations useful for carrying out such methods (e.g., an antibody that specifically binds to EMAP II in a pharmaceutically acceptable carrier) and screening techniques useful for identifying additional compounds that can be used for carrying out such methods are also disclosed.

Abstract: The invention includes kits for producing and using immunogenic compositions that include swine infertility and respiratory virus. The invention also includes vaccines and sera for treatment of Mystery Swine Disease (MSD), a method for producing the vaccine, methods for diagnosis of MSD, a viral agent that will mimic “mystery swine disease” and antibodies to the viral agent useful in diagnosis and treatment of MSD. The serum contains mammalian antibodies which are effective in treating MSD.

Abstract: The invention relates to (glyco-) proteins, in particular monoclonal antibodies, which have an immunoreactivity of >81%, preferably >90%. The inventive monoclonal antibodies are produced using a fluidized bed reactor in conjunction with a conventional protein-chemical purification method or preferably with a purification method involving less column chromatography. The monoclonal antibodies thus produced are suitable, in gamma-irradiated form, e.g. Tc-99m labelled, for the in vivo diagnosis of inflammatory diseases and bone marrow metastases. In alpha- or beta-irradiated form, e.g. astatine or Re-188 or Y-90 labelled form, the inventive monoclonal antibodies can be used, for example, in the treatment of leukemia.

Abstract: The present invention provides for modified forms of anti-CD52 antibodies with reduced numbers of potential T-cell epitopes that are expected to display decreased immunogenicity.

Abstract: This invention pertains to a method for treating ulcerative colitis. Specifically, the method comprises orally or rectally administering to a human having ulcerative colitis a therapeutically effective amount of an antibody which binds to a tropomyosin isoform associated with ulcerative colitis. In another embodiment, the invention pertains to a method for treating ulcerative colitis in a human which comprises the steps of (a) obtaining from a human a colon epithelial cell extract containing a tropomyosin isoform associated with ulcerative colitis; (b) purifying the tropomyosin isoform until the tropomyosin isoform is substantially homogeneous; (c) developing an antibody which binds to the tropomyosin isoform; and (d) orally or rectally administering to a human having ulcerative colitis a therapeutically effective amount of the antibody to bind to the tropomyosin isoform associated with ulcerative colitis.

Abstract: The purified nerve growth factor consisting of 116 amino acids from the venom of Naja kaouthia snake was fragmented by trypsin digestion. The fragments were isolated individually by high pressure liquid chromatography (HPLC). Thus separated fragments were tested for the biological activity of neurite growth on rat adrenal pheochromocytoma (PC12) cells. The fragment which showed the most activity was named ADESH. Subsequently, ADESH was sequenced. Synthetic ADESH was constructed using ten amino acids N L G E H P V C D S (SEQ. ID. NO: 3) of the fragment from its N-terminal is designated as AD-10. Different versions of synthetic ADESH such as AD-15 and AD-5 consisting of 15 and 5 amino acids respectively were constructed; having the sequence: N L G E H P V C D S T D T W V (SEQ. ID. NO: 2) for AD-15 and N L G E H (SEQ. ID. NO: 4) for AD-5. The synthetic AD-15 and AD-5 mimic the biological activity of the natural NGF.

Abstract: The present invention provides soluble CD39 polypeptides and compositions, and methods for inhibiting platelet activation and recruitment in a mammal comprising administering a soluble CD39 polypeptide.

Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.

Abstract: A method for producing a refolded, inactive form of recombinantly produced NS2/3 protease which comprises the steps of: a) purifying the protease from inclusion bodies in the presence of a chaotropic agent; and b) refolding the purified protease by contacting it with a reducing agent and lauryldiethylamine oxide (LDAO) in the presence of reduced concentration of chaotropic agent or polar additive. The invention further comprises a method for activating this refolded inactive NS2/3 protease by adding an activation detergent. This method produces large amounts of the active NS2/3 protease to allow small molecules and ligands to be screened as potential inhibitors of NS2/3 protease, which may be useful as therapeutic agents against HCV.

Abstract: The present invention relates to nucleic acid sequences encoding Ostertagia ostertagi proteins and to parts of such nucleic acid sequences that encode an immunogenic fragment of such proteins, and to DNA fragments, recombinant DNA molecules, live recombinant carriers and host cells comprising such nucleic acid sequences or such parts thereof. The invention also relate to Ostertagia ostertagi proteins and immunogenic parts thereof encoded by such sequences. Furthermore, the present invention relates to vaccines comprising such nucleic acid sequences and parts thereof, DNA fragments, recombinant DNA molecules, live recombinant carriers and host cells comprising such nucleic acid sequences or such parts thereof, proteins or immunogenic parts thereof and antibodies against such proteins or immunogenic thereof. Also, the inventions relates to the use of said proteins in vaccines and for the manufacture of vaccines.

Abstract: A method for treating a disease selected from diabetes mellitus and atherosclerosis, and a method for reducing triglycerides and/or increasing HDL cholesterol levels in the plasma of a subject. The method comprises administrating. to a subject an effective amount of crude Dunaliella powder, optionally together with an activator of nuclear receptors.

Abstract: The present invention provides a herpes virus in which a non-essential gene for replication is inactivated More particularly, the present invention provides a herpes virus in which a non-essential gene for replication present in a UL or US region is inactivated. More preferably, the non-essential gene for replication contains US3 or UL56. The herpes virus may be preferably a herpes simplex virus, and more preferably herpes simplex virus 1 or herpes simplex virus 2. The present invention provides a method, composition and use for treating various diseases or disorders including tumor and infectious diseases. The present invention also provides a method, composition and use for activating a prodrug.

Abstract: This invention relates to a novel mycobacterial protein named DES, which appears to share significant amino acid sequence homology with soluble stearoyl-ACP desaturases. The results of allelic exchange experiments, indicate that the des gene may be essential to the survival of mycobacteria. These results coupled with the surface localization, the unique structure of DES, and the fact this antigen is expressed in vivo, and DES protein induces a humoral response in human patients, indicate that the DES protein provides a new target for the design of anti-mycobacterial drugs. This invention provides methods of screening molecules that can inhibit the DES enzyme activity of purified DES protein, in order to identify antibiotic molecules that are capable of inhibiting the growth or survival of mycobacteria.

Abstract: The present invention relates to a vaccine for immunization against a viral infection caused by a virulent systemic feline calicivirus (VS-FCV), a novel, atypical and unusually virulent form of a calicivirus that results in a highly contagious and fatal hemorrhagic fever syndrome. The present invention further encompasses methods of immunizing cats against particular strains of VS-FCV.

Abstract: Disclosed is an invention related to the preparation and use of vaccines against pathogenic organisms, such as herpes virus. The vaccines hereof are based upon the use of truncated, membrane-free derivatives of a membrane-bound polypeptide from the pathogen. These polypeptides when incorporated into a vaccine composition afford protection against pathogenic challenge after administration.

Abstract: The present invention relates to the identification of bovine adenovirus sequence(s) essential for encapsidation and E1 transcriptional control regions. The present invention provides adenovirus expression systems, host cells and compositions comprising adenovirus vectors which comprise one or more BAV sequence(s) essential for encapsidation, as well as helper virus which express BAV sequences essential for encapsidation. The present invention also provides helper vectors comprising a BAV sequence essential for encapsidation which is used in a helper virus for propagating recombinant adenovirus. The present invention also provides adenovirus expression systems, host cells and compositions comprising adenovirus vectors which comprise modifications in BAV E1 transcriptional control regions. The present invention also provides methods for making adenovirus vectors comprising BAV sequence(s) essential for encapsidation as well as modifications in BAV E1 transcriptional control regions.

Abstract: Infection by P. carinii can be treated by administering methioninase optionally in combination with additional therapeutic agents, such as antibiotics.

Abstract: This invention comprises cellular vaccines and methods of using them in cancer immunotherapy, particularly in humans. The vaccines comprise a source of tumor-associated antigen, and a cytokine-secreting cell line. Tumor antigen may be provided in the form of primary tumor cells, tumor cell lines or tumor extracts prepared from the subject. In certain embodiments of the invention, the cytokine-secreting line is a separate tumor line that is allogeneic to the patient and genetically altered so as to produce a cytokine at an elevated level. Exemplary cytokines are IL-4, GM-CSF, IL-2, TNF-?, and M-CSF in the secreted or membrane-bound form. In these embodiments, the cytokine-producing cells provide immunostimulation in trans to generate a specific immune response against the tumor antigen.

Abstract: The subject-matter of the present invention is a stable anhydrous composition for cosmetic or pharmaceutical use comprising at least one silicone oil and at least one pigment, wherein said composition further comprises at least one oxyalkylenated silicone substituted at the ? and ? positions.

Abstract: One aspect of the invention is a system for treating vascular conditions, including a catheter, a stent coupled to the catheter, and a polymeric coating on the stent comprising at least one conjugated drug. Each conjugated drug includes a control agent and a bioactive agent, where the control agent controls the elution rate of the bioactive agent.

Abstract: An adhesive including a mixture of isocyanate capped molecules formed by reacting multi-isocyanate functional molecules with multi-functional precursor molecules including terminal functional groups selected from the group consisting of a hydroxyl group, a primary amino group and a secondary amino group. Preferably, the functional groups are hydroxyl groups. The multi-functional precursor compounds are biocompatible. Multi-amine functional precursors of the multi-isocyanate functional molecules are also biocompatible. As discussed, above, the mixture of molecules preferably has an average isocyanate functionality of at least 2.1 and, more preferably, has an average isocyanate functionality of at least 2.5. As also described above, the mixture of molecules preferably has a viscosity in the range of approximately 1 to approximately 100 centipoise. The mixture of molecules forms a crosslinked polymer network upon contact with the organic tissue in the presence of water.

Abstract: Oral dosage form for food and food supplement as well as dietetics comprising polyunsaturated acids in a xylose-hardened gelatine capsule with a retarded release time.

Abstract: The invention describes pharmaceutical preparations with retarding active ingredient release, which consist of mixtures of powdery teicoplanin and at least one powdery, water soluble salt form of gentamicin, clindamycin, kanamycin, amikacin, tobramycin, vancomycin, moxifloxacin and ciprofloxacin and an inorganic and/or organic adjuvant. The pharmaceutical preparations are used as permanent or as temporary implants in the form of tablets, molded bodies, fibers and granules.

Abstract: The present invention relates to a pharmaceutical composition comprising a non-viable cell lysate and at least one antiflocculant and/or antisedimentation agent(s). The pharmaceutical composition of the present invention comprising the cell lysate is in the form of a solution or a suspension or a lyophilisate, in particular, the homogenized cell lysate compositions are in the form of solutions or suspensions or lyophilisates. The present invention further discloses processes for the production and the use of the pharmaceutical composition.

Abstract: Weather resistant granular baits containing an attractant system are disclosed. Methods of making and using the baits are also disclosed.

Abstract: The process of extracting small molecular ingredients from biological materials under super high pressure is a process which makes use of super high pressure to extract small molecular active ingredients from biological materials, especially natural products, which mainly consists of extracting the mixture of solid raw material and extraction solvent under increased pressure. Said process comprises the following steps: the step of pretreatment, crash and formulation; the step of closure, charging the formulated mixture of raw material and extraction solvent into high pressure container, then closing the high pressure container; the step of increasing pressure, increasing the pressure of the high pressure container from 100 Mpa to the predefined pressure of 1000 Mpa; the step of holding pressure, holding the predefined pressure for 3-30 minutes; the step of releasing pressure, releasing the pressure of the high pressure container to normal pressure, removing the mixture.

Abstract: Methods and compositions relating to leaf extracts obtained from Morinda citrifolia leaves. Methods and compositions relating to a leaf serum created from combining leaf extract and fruit juice from the Morinda citrifolia L. plant. Methods and compositions relating to leaf extract compositions comprising one or more of the leaf extracts and leaf serums.

Abstract: Described is a process for effecting the relaxation of a tensive back, shoulder or neck muscle of a human mammal for a substantial period of time. The process of our invention consists essentially of the step of continuously or periodically administering to said human mammal through inhalation over a stress reactivity-reducing, tensive back, shoulder or neck muscle-relaxing period of time, a stress reactivity-reducing, tensive back, shoulder or neck muscle-relaxing quantity and concentration of one or more fragrance compositions having an aroma profile including one or more of a rose, floral, musky, ambery, sweet and/or powdery aroma notes.

Abstract: Cyclooxygenase-2 enzyme inhibiting withanolides are described. In particular, compounds from Withania somnifera are the preferred source of the withanolides, although they can be from other plant sources. The COX-2 inhibition is selective over COX-1.

Abstract: Cyclooxygenase-2 enzyme inhibiting withanolides are described. In particular, compounds from Withania somnifera are the preferred source of the withanolides, although they can be from other plant sources. The COX-2 inhibition is selective over COX-1.